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Dietmar SteverdingAbstract
The ancestor of Trypanosome cruzi was probably introduced to South American via bats approximately 7-10 million
years ago. When the first humans arrived in the New World, a sylvatic cycle of Chagas disease was then already well
established. Paleoparasitological data suggests that human American trypanosomiasis originated in the Andean area
when people founded the first settlements in the coastal region of the Atacama Desert. Identification of T. cruzi as
the etiological agent and triatome bugs as the transmission vector of Chagas disease occurred within a few years at
the beginning of the 20th century. History also teaches us that human activity leading to environmental changes, in
particular deforestation, is the main cause for the spread of Chagas disease. Recently, migration of T. cruzi-infected
patients has led to a distribution of Chagas disease from Latin America to non-endemic countries in Europe, North
America and western Pacific region.
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Chagas disease or American trypanosomiasis is a zoonotic
infectious disease affecting humans in Latin America. The
disease is caused by the protozoan flagellate Trypanosoma
cruzi that lives and multiplies within cells from a variety
of tissues. The parasite is usually transmitted via the
faeces of blood-sucking bugs belonging to the subfamily
Triatominae (kissing bugs or conenose bugs), with
Triatoma infestans, Rhodnius proxilus and Panstrongylus
megistus being the most important vectors. As T. cruzi
cannot penetrate intact skin, it enters the human body
through microlesions that have been introduced and con-
taminated with faeces when individuals scratch the itching
vector’s bite. In addition, T. cruzi is able to break through
intact mucous membranes (such as the conjunctiva and
the gastric epithelium). Other modes of transmission in-
clude blood transfusion, organ transplantation, via breast
milk, congenitally via the placenta and by ingestion of
contaminated food and drink. Chagas disease is endemic
in all South and Central American countries as well as
in Mexico [1]. In addition, the southern half of the United
States contains enzootic cycles of T. cruzi and autoch-
thonous vector-borne human infections have been re-
ported in Texas, California, Tennessee, Louisiana and
Mississippi [2,3].Correspondence: dsteverding@hotmail.com
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unless otherwise stated.There are two phases during the course of Chagas dis-
ease. The acute phase begins 6-10 days after infection and
lasts for about 4-8 weeks [4]. In most cases, the acute phase
passes unnoticed as the clinical symptoms are nonspecific
(including fever, hepatosplenomegaly or lymphadenopathy)
and are typical for many infections [5]. As a specific symp-
tom, inflammatory oedema at the site of infection may be
observed. If the entry site is the skin, the swelling is known
as a chagoma. In case the entry point is the eye, a unilateral
periorbital swelling, a so-called Romaña’s sign, may develop.
Acute myocarditis and acute meningoencephalitis can be
occasionally seen in young children aged 1-5 years and is in
most cases fatal [4]. Abnormalities in the ECG are observed
in about 50% of cases which usually disappear later in the
disease course [6]. During the acute phase, circulating try-
panosomes can be easily found in the blood of patients [5].
Eventually, the parasite and the host reach an immuno-
logical balance and the disease enters the chronic phase.
In this phase, the parasitaemia is greatly reduced and the
patients become asymptomatic. Most patients remain in a
so-called indeterminate (latent) chronic stage for the rest
of their lives and do not develop any chronic symptoms.
However, 15-30% of infected people will enter the deter-
minate (symptomatic) chronic stage of the disease associ-
ated with the manifestation of organ damage [5]. This
usually happens 10-25 years after the initial infection [5].
Typical manifestations are the dilatation of the heart
(chronic chagasic cardiomyopthy) and/or parts of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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though the clinical manifestation of megaoesophagus
and megacolon can be extremely debilitating conditions
for many patients, the development of cardiomyopathy
is a life-threatening problem in most cases. The dif-
ferent pathologies of Chagas disease are caused by six
discrete typing units (DTUs) of T. cruzi (TcI-TcVI), which
have distinct geographical distributions and extensive gen-
etic diversity [7].
In contrast to African trypanosomes which were import-
ant selective factors in the human evolution [8], American
trypanosomes affected human beings only recently who
arrived in the New World less than 15,000 years ago [9].
Review
Origin of T. cruzi
Phylogenetic analysis of 18S rRNA sequences indicates
that salivarian trypanosomes (the T. brucei clade group-
ing those trypanosomes that are transmitted by bites)
diverged from the stercorarian trypanosomes (T. cruzi
clade grouping those trypanosomes that are transmitted
by faecal contamination) approximately 100 million years
ago [10]. As at the same time South America, Antarctica
and Australia separated from Africa, it was suggested that
T. cruzi and related trypanosomes evolved in isolation in
early terrestrial mammals [11]. This idea is known as the
southern super-continent hypothesis. Based on this sce-
nario one would expect a high diversity of T. cruzi clade
trypanosomes in South American terrestrial mammals
provided that they had been present on the continent
since the break up the southern super-continent 40 mil-
lion years ago [11]. However, this is not the case. No bona
fide species have been discovered in the T. cruzi clade
from any South American terrestrial mammal to date
[11], i.e., no co-evolution generating host species specific
genotypes has occurred. In addition, as T. cruzi clade try-
panosomes are also present in land mammals from Africa
and Australia [11], the role of geographical isolation in the
evolution of T. cruzi is questionable.
Recent molecular evidence indicates that T. cruzi has
evolved from a bat trypanosome, a scenario known as
the bat seeding hypothesis [11]. This idea is supported
by the fact that the closest genetically characterised rela-
tive of T. cruzi is T. marinkellei from South American
bats [10,12-14]. Both diverged approximately 6.5-8.5 mil-
lion year ago [15,16] and could be regarded as subspecies
(i.e. T. c. cruzi and T. c. marinkellei) [17]. The recently de-
scribed T. erneyi and T. livingstonei found in bats from
Mozambique [18,19], and T. dionisii from Old and New
World bats [10,12,14,20] are also close relatives of T. cruzi.
Moreover, T. cruzi has been detected in South American
bats [12,21,22] with one specific genotype, TcBat, only
found in bats so far [23]. TcBat is most closely related to
T. cruzi TcI which primarily is associated with opossumsand conenose bugs of the genus Rhodnius in arboreal eco-
topes [11]. Based on these facts it is reasonable to suppose
that the common ancestor of the members of the T. cruzi
clade was a bat trypanosome. Presumably, trypanosome-
infected bats have colonised South America about 7-10
million years ago via North America [24]. Then, various
independent bat trypanosome lineages switched from bats
into terrestrial mammals probably facilitated by inverte-
brate vectors feeding on both bats and terrestrial mam-
mals living in the same arboreal ecotopes [10]. One such
switch gave rise to T. cruzi in the Pliocene [25]. The diver-
sification of T. cruzi into the current DTU lineages TcI-
TcVI and TcBat started quite recent about 1-3 million
years ago [25].
Pre-Columbian time
There is evidence that soon after having populated South
America humans became infected with T. cruzi. The earli-
est detection of a T. cruzi infection in a human comes
from a 9000 year old Chinchorro mummy through PCR
amplification of kinetoplasid DNA sequences [26]. The
Chinchorros were the first people identified to settle along
South American’s coastal region of the Atacama Desert in
southern Peru and northern Chile. T. cruzi infections were
also found in mummies of subsequent cultures that suc-
ceeded the Chinchorros and were living in the same area
up to the time of the Spanish conquest in the 16th century
[26]. The prevalence rate for T. cruzi infection in these
populations was 41% without any significant differences
among the individual cultures indicating that already in
pre-Columbian time Chagas disease was widely spread in
civilised societies [26]. Infections with T. cruzi were also
detected in human remains from other archaeological ex-
cavation sites in America [27]. For example, T. cruzi DNA
was found in a 560 year old partially mummified human
body and in a 4,500-7,000 year old human bone frag-
ment both unearthed in the Peruaçu Valley in the State of
Minas Gerais, Brazil [28,29]. Another case of a prehis-
toric T. cruzi infection was reported in a 1,150 year old
mummy recovered from the Chihuahuan Desert near the
Rio Grande in Texas [27]. In addition to the detection of
T. cruzi in human remains, several exhumed mummies
also showed clinical signs of Chagas disease [26-28,30].
Further evidence of American trypanosomiasis in Pre-
Columbian times comes from Peruvian ceramics dated to
the 13th-16th centuries showing possible representa-
tions of Chagas disease [31]. This also included a head
with a unilateral swelling of the eyelid reminiscent of the
Romaña’s sign [31].
Based on the paleoparasitological data, it has been
hypothesised that Chagas disease originated in the Andean
region [32]. It is believed that the Chinchorro people were
the first to leave a nomadic lifestyle and to settle down to
start arable farming and livestock breeding [26,30,31]. Upon
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in the sylvatic cycle of T. cruzi, and gradually a domestic
cycle of transmission of Chagas disease emerged [26,31,32].
The development of a domestic T. cruzi transmission
cycle was facilitated by the ability of some species of tria-
tomine bugs, in particular T. infestans, to adapt easily to
more open vegetation and to develop a preference for
human dwellings over time [33]. In this context, it is im-
portant to note that the establishment of agricultural set-
tlements usually involves some degree of deforestation.
Crucially, deforestation is strongly linked to an increase in
the prevalence of Chagas disease [33]. This connection is
supported by the fact that American trypanosomiasis is
absent in the indigenous inhabitants of the Amazon re-
gion, who used different socio-environmental patterns of
land occupation including open communal huts un-
favourable for vector colonisation, continuous mobility,
and absence of domestic animals which all together hinder
vector transmission of Chagas disease [34].
Modern times
16th-19th century
From the 16th century onwards, there are several accounts
by travellers and physicians describing patients with dis-
ease symptoms reminiscent of American trypanosomiasis.
A first suggestive clinical report relating to possible intes-
tinal symptoms of Chagas disease comes from a book
published in 1707 by the Portuguese physician Miguel
Diaz Pimenta (1661-1715) [35]. Therein he described a
condition, which was known as “bicho”, “that causes the
humours to be retained, causing the patient to have little
desire to eat”. However, a more detailed analysis of the
text suggests that the symptoms described refer more
likely to haemorrhoids rather than to the clinical picture
of a chagasic megacolon [36]. A clearer account on the
megavisceral syndrome of Chagas disease comes from an-
other Portuguese physician, Luís Gomes Ferreira (1686-
1764), who wrote in 1735 that “the corruption of bicho is
nothing else but an enlargement and distension of the rec-
tum” [37,38]. Other records described a condition known
then as “mal de engasgo” which probably refers to dyspha-
gia, the difficulty in swallowing [39-41]. For example, the
Danish physician Theodoro J. H. Langgaard (1813-1884),
who emigrated to Brazil in 1842, gave the following char-
acteristic description of the condition: “…usually the food
bolus only passes up to the cardia above the stomach. …
Some patients are able to force the descent of the food
into the stomach by drinking a small amount of water
after each mouthful of ingested food. … As a result of the
imperfect nutrition the patients begin to lose weight, be-
come emaciated…” [37,41]. Many more storied references
to Chagas disease can be found in an article by Guerra
[42]. All these historical accounts indicate that Chagas dis-
ease was present in Latin America from the beginning ofthe 16th century and that it was affecting indigenous
people as well as the conquistadors.
There are also many reports of triatomine bugs long
before their role as vector for T. cruzi was discovered
(reviewed in [31] and [37]). Probably the most famous
account of a kissing bug comes from Charles Darwin
(1809-1882). On the 25th of March 1835 he noted in his
diary which he kept during his voyage of The Beagle: “At
night I experienced an attack (for it deserves no less a
name) of the Benchuca (a species of Reduvius) the great
black bug of the Pampas. It is most disgusting to feel
soft wingless insects, about an inch long, crawling over
one’s body. Before sucking they are quite thin, but after-
wards become round and bloated with blood, and in this
state they are easily crushed. They are also found in the
northern part of Chile and in Peru. One which I caught
at Iquique was very empty. When placed on the table, and
though surrounded by people, if a finger was presented,
the bold insect would immediately draw its sucker, make a
charge, and if allowed, draw blood. No pain was caused by
the wound. It was curious to watch its body during the act
of sucking, as it changed in less than ten minutes, from
being as flat as a wafer to a globular form. This one feast,
for which the benchuca was indebted to one of the offi-
cers, kept it fat during four whole months; but, after the
first fortnight, the insect was quite ready to have another
suck” [43]. Based on this encounter with a kissing bug and
his prolonged gastric and nervous symptoms, it was
even hypothesised that Darwin was suffering from Chagas
disease later in his life. However, Chagas disease is a most
unlikely diagnosis for Darwin’s chronic illness as the
symptoms abated as he aged, as he did not seem to have
any of the typical chagasic symptoms and as he had some
of the symptoms already before the Beagle voyage [37].
Despite all these reports, the critical role of triatomine
bugs in transmitting Chagas disease remained undiscov-
ered until 1909.
20th century
In 1908, during an anti-malaria campaign in support of
the construction of a railway track in the North of the
state of Minas Gerais, the Brazilian hygienist and bacteri-
ologist Carlos Chagas (1879-1934) (Figure 1) was made
aware by a railroad engineer of large blood-sucking insects
which lived en masse in local dwellings and bit sleeping
people preferentially in the face [44]. To see whether these
bugs harboured potential pathogens, Chagas dissected
them and found numerous trypanosomes in their hindgut
which he named T. cruzi in honour of his mentor, the
Brazilian physician and bacteriologist Oswaldo Cruz
(1872-1917) (Figure 2) [45]. Some infected bugs were sent
to Cruz in Rio de Janeiro, where they were allowed to bite
marmoset monkeys. Within 20-30 days, the monkeys be-
came infected and many trypanosomes were detected in
Figure 1 Carlos Ribeiro Justiniano das Chagas in his laboratory
at the Federal Serotherapy Institute in Manguinhos, Rio de
Janeiro. The Brazilian hygienist, scientist and bacteriologist identified
the protozoan parasite T. cruzi as the causative agent of Chagas
disease. Photo taken from Wikimedia Commons.
Figure 2 Oswaldo Gonçalves Cruz. The Brazilian physician,
bacteriologist and epidemiologist was the mentor of Carlos Chagas
who discovered American trypanosomiasis. Cruz founded in 1900
the Federal Serotherapy Institute which was renamed in 1905 to
Manguinhos Experimental Pathology Institute, then in 1908 to
Oswaldo Cruz Institute and finally in 1974 to Oswaldo Cruz
Foundation (Fundação Oswaldo Cruz (Fiocruz)). Photo taken from
Wikimedia Commons.
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that the parasite was infective to several other laboratory
animals [44]. Chagas was sure that he had found a patho-
genic organism of a human infectious disease but did not
know what kind of sickness it was. The breakthrough
came in 1909 when he was called to examine a two year
old girl named Berenice who was feverish with enlarged
spleen and liver and swollen lymph nodes [44]. On first
examination, no parasites were found but four days later,
on the 14th of April 1909, numerous trypanosomes were
spotted in her blood with similar morphology to those
previously detected in infected marmoset monkeys [44].
Chagas had discovered a new human disease which soon
bore his name. He gave a detailed clinical description of
the acute phase of the disease and linked the infection
with some chronic symptoms of the illness which was re-
markable considering that the chronic phase of American
trypanosomiasis usually appears decades after the first in-
oculation with T. cruzi (reviewed in [46]). Interestingly, his
first patient Berenice never developed determinate chronic
Chagas disease and died at the age 73 years on unrelated
causes [47]. However, she was infected with T. cruzi for
her whole life as was confirmed by the isolation of para-
sites when she was 55 and 71 years old [47]. In 1912,
Chagas reported that he had detected T. cruzi in an ar-
madillo and thus found the first sylvatic reservoir host
[48]. Gradually, more and more sylvatic reservoir animals
of Chagas disease were discovered providing evidence for
an enzootic cycle of T. cruzi.Without doubt, the discovery of American trypanosom-
iasis is inseparably linked to Carlos Chagas. However,
other researchers have also contributed to the findings.
Oswaldo Cruz’s mentoring and the institute he and the
Brazilian government founded in 1900 to fight endemic
diseases played an important role in the uncovering of
Chagas disease [49]. The identification and characterisa-
tion of T. cruzi was the result of collaboration with the
Czech zoologist and parasitologist Stanislaus von Prowazek
(1875-1915) who was invited by Cruz to spend six months
at the Federal Serotherapy Institute to conduct research
(reviewed in [50]). The intracellular life cycle stage of
T. cruzi, the amastigote form, was described by Chagas’
colleague, the Brazilian pathologist Gaspar de Oliveira
Vianna (1885-1914), in both heart and skeletal muscle
cells [51]. The mode of transmission of T. cruzi was estab-
lished by the French parasitologist Alexandre Joseph
Émile Brumpt (1877-1951) who provided in 1912 clear
evidence that the infection resulted not by inoculation but
by contamination of the bite wound with parasite contain-
ing faeces left behind by the bugs [52].
Benznidazole
Nifurtimox
Crystal Violet
Lindane
Deltamethrin
Figure 3 Chemical structures of compounds used in the
treatment and control of Chagas disease. Benznidazole and
nifurtimox are drugs for chemotherapy of acute Chagas disease.
Crystal Violet is used in blood banks to eliminate T. cruzi from
infected human blood. Lindane (an organochlorine) and
deltamethrin (a synthetic pyrethroid) are insecticides used in the
control of triatomine vectors.
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worldwide recognition and acknowledgement but also
animosity and envy in his own country [53]. This strong
opposition not only may have cost him the Nobel Prize,
for which he was nominated twice in 1913 and 1921, but
also halted the interest in the new disease for almost
20 years [49,53]. The research on Chagas disease resumed
in the 1930s when the Argentine physician and epidemi-
ologist Salvador Mazza (1886-1946) described more than
a thousand cases in the Argentine Chaco province [54,55].
Mazza was also the first who raised the possibility that
Chagas disease could be transmitted by blood transfusion
[49]. By the introduction of serodiagnostic tests in the
1940s it was eventually shown that infections with T. cruzi
were widespread in Latin America [56].
Testing of compounds for treatment of Chagas disease
began soon after the discovery of the infection, but with-
out effective results (reviewed in [57]). It took another
50 years before the eventual development of two com-
pounds into drugs for chemotherapy of American tryp-
anosomiasis. In 1966, Hoffmann-La Roche introduced
benznidazole (Figure 3) for treatment of Chagas disease
[57]. Nifurtimox (Figure 3) was made commercially
available as antichagasic medicine by Bayer in 1970 [57].
The production of nifurtimox was suspended in 1997
due to lack of demand, but resumed in 2000 because the
compound became part of a new combination therapy
for treatment of African sleeping sickness [57,58]. Ini-
tially, both drugs were primarily used for treatment of
acute cases of Chagas disease because they were consid-
ered less effective in the chronic phase [57]. In 1953 it was
discovered that the dye crystal violet (aka Gentian Violet;
Figure 3) kills T. cruzi in blood preservations [59]. Since
then the dye has been widely employed in blood banks in
endemic areas to eliminate the parasite from blood used
for transfusion. Vector control started in the 1940s when
the first organochlorine insecticides were developed.
Although DTT was quickly found to be ineffective against
most triatomine bugs, two other compounds, lindane
(Figure 3) and dieldrin were highly effective in killing the
vector when sprayed over house walls [60,61]. The intro-
duction of synthetic pyrethroid insecticides (e.g. delta-
methrin (Figure 3) and cyfluthrin) in the early 1980s was a
major advance in the control of domestic triatomines as
they are more cost-effective and leave no unpleasant smell
and marks on the treated walls [60,61].
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Figure 4 Estimated number of Chagas cases in non-endemic countries. Only countries with more than 100 expected cases of T. cruzi
infection among immigrants were included. The insert shows those countries with less than 5000 expected cases. Data were taken from [70]
(United States, Canada and Australia) and [71] (European countries).
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At present about 7-8 million people are estimated to be
infected with T. cruzi, mostly in Latin America, and more
than 25 million people are at risk of contracting Chagas
disease [1,62]. In 2008 alone, more than 10,000 deaths
from Chagas disease were reported [62]. Since the 1990s,
multinational initiatives have led to significant reductions
in the number of acute cases of Chagas disease and in the
presence of domestic triatomine vectors in many endemic
regions of Latin America [1]. Indoor residual spraying has
even lead in the elimination of R. proxilus in Central
America [63]. Despite these achievements in parasite and
vector control, new challenges have arisen. These include
recent outbreaks of Chagas disease in the Amazon basin,
a region previously thought to be free of the illness, due to
oral transmission via contaminated food [64-66], and the
ongoing active transmission of Chagas disease in the
Bolivian Chaco region in spite of vector control had
been in progress there since 2000 [67]. Another problem
is the emergence of insecticide resistant triatomine vectors
in the Gran Chaco, a region located west of the Paraguay
River and east of the Andes [68].
Despite many efforts over the past decades, no drug for
the treatment of chronic Chagas disease has been devel-
oped so far. However, according to new recommendationspublished in 2005 and 2007 treatment with nifurtimox
and benznidazole is indicated for patients with acute infec-
tion as well as for patient < 18 years of age with chronic in-
fection [69,70]. Moreover, treatment should be offered to
women in reproductive age as well as to adults < 50 years
of age with evidence of chronic infection [69,70]. Treat-
ment is also indicated in immunosuppressed patients with
reactivated infection [69,70].
The costs for treatment and prevention of Chagas dis-
ease are another current challenge and are a huge burden
for the health system of affected countries. For example,
in Colombia alone, the costs for medical care of all Chagas
patients and for spraying insecticides to vector controls
were estimated to be US$ 267 million and US$ 5 million
in 2008, respectively [71].
Moreover, Chagas disease is increasingly becoming a
global health problem. This is due to migration of people
infected with T. cruzi from endemic countries to North
America, Europe and the western Pacific region. The total
estimated number of Chagas patients outside Latin Amer-
ica is more than 400,000 with the USA being the most af-
fected country accounting for three-fourths of all cases
(Figure 4) [72,73]. In Europe alone, the number of patients
that will develop chronic chagasic cardiomyopathy is esti-
mated to be as high as 54,000 [73].
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It is evident from the history of Chagas disease that an-
thropogenic environmental changes are the primary
causes for the transmission of the infection to people.
Deforestation seems to be the main factor as it brings
people into closer contact with disease-carrying vectors.
This is supported by the fact that the transmission of
Chagas disease was first induced in ancient times when
humans started to clear land for settlements and agricul-
ture. Mining, lumbering and urbanisation are other hu-
man activities linked to deforestation which led to an
increase in the spread of Chagas disease in more recent
times. From the history of Chagas disease one can also
learn that triatome vectors have a remarkable ability to
quickly adapt to newly created environments and to new
hosts. This adaptability of these insects has led to the es-
tablishment of domestic transmission cycles between com-
panion animals and humans, which seems to have been
crucial for the distribution of Chagas disease throughout
Latin America. Through migration Chagas disease has
even now become a worldwide health concern.
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